



SAFETY AND RISK ASSESSMENT OF PEPTIDES IN COSMETIC PRODUCTS

C. DE ROY¹, S. MISHRA², M. AUTIERO¹, F. TENCALLA¹ AND T. PETRY¹

ToxMinds BVBA, Brussels, Belgium¹; ToxMinds India Consulting Pvt. Ltd., Bangalore, India²

Introduction

Recently, there has been increased interest in launching cosmetic products containing peptides to prevent or reduce skin aging in skincare cosmetics. The peptides can be extracted from several sources including plants, animals, or microorganisms, or can be produced synthetically.

Peptides may be biologically active and have the potential to interact with skin. Thus, in line with the requirements stipulated under the EU Cosmetics Product Regulation ((EC) No 1223/2009) (EU, 2009), their safety must be established by selecting an appropriate Point of Departure (PoD) for systemic toxicity and a sufficiently high Margin of Safety (MoS) under cosmetic product use conditions.


In the context of read across, we have established a step-wise process to identify analogues and determine their suitability, in accordance with OECD guidelines and the ECHA read across assessment framework (RAAF) (ECHA, 2017). To increase confidence in the safety assessment, an additional analysis is conducted to determine whether the peptide of interest presents sequence similarity to known human proteins. Specifically, a BLAST analysis is performed to compare the peptide sequence to the National Center for Biotechnology Information (NCBI) database and identify the best similarity matches. A high degree of similarity (greater than 80%) with a known human protein can help assess the toxicological profile of the peptide. The safety assessment may be supported by results of in vitro testing to

This poster presents a weight-of-evidence approach to assess the safety of cosmetic products containing peptides, primarily based on the use of read across and BLAST (Basic Local Alignment Search tool) (NCBI, 2024).

demonstrate hydrolysis and complemented with toxicological data on individual amino acids.

A case study is presented to demonstrate the safety assessment approach for data-poor peptides in cosmetics products.

Workflow for the safety assessment of peptides in cosmetics



Case study : Data-poor peptide

OBJECTIVE

To establish a PoD and a sufficient MoS for peptide A, which is used to prevent or reduce skin aging in skincare cosmetics, using the systemic toxicity data available for an 'analogue'.



Figure 1: Peptide A

Steps	Available information		
Literature search and data gaps identification	Available in vitro experimental data on the peptide A: skin and eye irritation, skin sensitisation, Ames test, and phototoxicity. Data gaps: acute toxicity, repeated dose toxicity, clastogenicity, carcinogenicity, reproductive, and developmental toxicity.		
Analogue identification	Chemical name	Structure	
and evaluation	Analogue: Bacitracin	$3L-Leu \qquad 5L-lle $	uan <i>et al.,</i> 2018)

Analogue suitability evaluation Based on chemical structure and reactivity, physicochemical properties, and metabolic pathway using tools such as the OECD QSAR Toolbox, Epi Suite[™] and Meteor[™], complemented with expert judgment

Evaluation of the similarities between the peptide and the protein A high degree of similarity of the amino acid sequence (> 80%) is considered to be relevant

Review of the available information Considering the systemic toxicity data on the analogue and available data on the peptide (in vitro assays and BLAST search)

Safety assessment based on a weight-of-evidence approach Including additional testing using NAMs

11D-Asp

Analogue evaluation:

- The analogue presents an acceptable similarity index (Dice index > 0.54). In addition, when comparing the amino acid composition, bacitracin shares three amino acids with peptide A.
- The analogue shares key functional groups with peptide A. Bacitracin also contains additional functional groups due to the presence of different amino acids.
- The (Q)SAR analysis using the OECD QSAR Toolbox v.4.6 showed that the analogue presents the same structural alerts for systemic toxicity, genotoxicity, carcinogenicity, and repeated dose. Bacitracin does not present an alert for eye irritation, while it presents an additional alert related to sensitisation.
- Bacitracin presents physicochemical properties in the same range compared to the target substance.
- Finally, in vivo metabolism data is available for bacitracin, which has been shown to undergo hydrolysis via peptidases as first metabolic reaction (EMEA, 1998). The target substance is also predicted by Meteor[®] Nexus (Judson *et al.*, 2015) v.3.2.0 to undergo hydrolysis as first metabolic reaction.

BLAST analysis identified a known human protein with a high degree of similarity. In fact, the target substance Identification shows 83% sequence similarity with the human immunoglobulin heavy chain junction region, corresponding to a part of the antigen recognition site for the antigen – antibody interaction.

human peptides to support repeated dose toxicity data of the analogue

of similar

Nation	stp suite » results for RID-BTF9R4AG013	Home	Recent Results Saved Strategies He
< Edit Search	Save Search Search Summary 🗸		/ideos DBack to Traditional Results Pa
A			
b Title	Protein Sequence	Filter Results	
D	BTF9R4AG013 Search expires on 08-15 22:20 pm Download		
ogram	BLASTP ? Citation ~	Organism only top 20 will appear	exclud
atabase		Type common name, binomial, taxid	or group name
	a construction of the second sec	+ Add organism	
Jery ID	Icl Query_9333707	Descent Identity Earlier	0
escription	unnamed protein product amino acid	Percent Identity E value	Query Coverage
olecule type		to	to
uery Length ther reports	6 Distance tree of results Multiple alignment MSA view		Filter Reset
Descriptions	Compare these results agains Graphic Summary Alignments Taxonom	new Clustered nr database 📀 BLAST	
Sequences p	Graphic Summary Alignments Taxonom		ect columns Y Show 100 Y
Sequences p	Graphic Summary Alignments Taxonom	Download ~ Sel	results Multiple alignment MSA View
Sequences p	Graphic Summary Alignments Taxonom	Download 🗸 Sel	results Multiple alignment MSA View
Sequences p	Graphic Summary Alignments Taxonom producing significant alignments	Download V Sel GenPept Graphics Distance tree of I Scientific Name Max Total Qu	results Multiple alignment MSA View ery E Per. Acc. ver value Ident Len Accession
Sequences p	Graphic Summary Alignments Taxonom producing significant alignments 100 sequences selected Description ized protein KIAA0513 isoform a [Homo sapiens] ized protein KIAA0513 isoform b [Homo sapiens]	Download Selection GenPept Graphics Distance tree of I Scientific Name Max Score Total Quadratic Quadrati	tesults Multiple alignment MSA View ery E Per. Acc. var Ident Len Accession 0% 18 83.33% 411 NP_001273494. 0% 18 83.33% 401 NP_001273495.
Sequences p	Graphic Summary Alignments Taxonom producing significant alignments 100 sequences selected Description ized protein KIAA0513 isoform a [Homo sapiens] ized protein KIAA0513 isoform b [Homo sapiens] ized protein KIAA0513 isoform b [Homo sapiens]	Download Selection GenPept Graphics Distance tree of I Scientific Name Max Score Total Quadratic Homo sapiens 22.3 22.3 10	Per Acc. ver Value Ident Len Accession 0% 18 83.33% 411 NP_001273494 0% 18 83.33% 401 NP_001273495 0% 19 83.33% 198 KAI2579985.1
Sequences p select all uncharacter vuncharacter vuncharacter vuncharacter vuncharacter vuncharacter	Graphic Summary Alignments Taxonom producing significant alignments 100 sequences selected Description ized protein KIAA0513 isoform a [Homo sapiens] ized protein KIAA0513 isoform b [Homo sapiens] ized protein KIAA0513 isoform b [Homo sapiens] until heavy chain junction region [Homo sapiens]	Download Selection GenPept Graphics Distance tree of I Scientific Name Max Total Quadratic Homo sapiens 22.3 22.3 10 Homo sapiens 21.8 21.8 10	Per Acc. ver Value Ident Len Accession 0% 18 83.33% 411 NP_001273494 0% 18 83.33% 401 NP_001273495 0% 19 83.33% 198 KAI2579985.1 0% 23 83.33% 16 MBN4474536.1
Sequences p select all uncharacter vuncharacter vuncharacter vuncharacter vuncharacter vuncharacter vuncharacter	Graphic Summary Alignments Taxonom producing significant alignments	Download Selection GenPept Graphics Distance tree of I Scientific Name Max Total Quadratic Homo sapiens 22.3 22.3 10 Homo sapiens 21.4 21.4 21.4	Per Acc. Ver Value Ident Len Accession 0% 18 83.33% 411 NP_001273494 0% 18 83.33% 401 NP_001273495 0% 19 83.33% 198 KAI2570985.1 0% 23 83.33% 16 MEN4474536.1 1% 27 100.00% 12 MEN42939365.1
Sequences p select all uncharacter vuncharac	Graphic Summary Alignments Taxonom producing significant alignments	Download Selection GenPept Graphics Distance tree of I Scientific Name Max Total Quadratic Homo sapiens 22.3 22.3 10 Homo sapiens 22.3 22.3 10 Homo sapiens 22.3 22.3 10 Homo sapiens 21.8 21.8 10 Homo sapiens 21.4 21.4 83 Homo sapiens 21.4 21.4 83	Per. Acc. ver value Ident Len Accession 0% 18 83.33% 411 NP_001273494 0% 18 83.33% 401 NP_001273494 0% 18 83.33% 401 NP_001273495. 0% 19 83.33% 198 KAI2579985.1 0% 23 83.33% 16 MEN4474536.1 1% 27 100.00% 12 MEN429385.1 1% 29 100.00% 13 MEN4432146.1
Sequences p select all uncharacter vurcharac	Graphic Summary Alignments Taxonom producing significant alignments	Download Selection GenPept Graphics Distance tree of I Scientific Name Max Total Quadratic Homo sapiens 22.3 22.3 10 Homo sapiens 22.3 22.3 10 Homo sapiens 21.8 21.8 10 Homo sapiens 21.4 21.4 21.4 Homo sapiens 21.4 21.4 21.4	Per. Acc. ver value Per. Acc. 1dent Len Accession 0% 18 83.33% 411 NP_001273494 0% 18 83.33% 401 NP_001273495. 0% 19 83.33% 408 MEN4474536.1 0% 23 83.33% 16 MEN4474536.1 1% 27 100.00% 12 MEN429385.1 1% 29 100.00% 13 MEN4432146.1 1% 30 100.00% 14 MBB171373.3.1
Sequences p select all uncharacter vurcharac	Graphic Summary Alignments Taxonom producing significant alignments	Complexit Selection GenPept Graphics Distance tree of tree Scientific Name Max Total Quadratic Homo sapiens 22.3 22.3 10 Homo sapiens 22.3 22.3 10 Homo sapiens 21.8 21.8 10 Homo sapiens 21.4 21.4 21.4	Per. Acc. ver Value Per. Acc. 1dent Len Accession 0% 18 83.33% 411 NP_001273494 0% 18 83.33% 401 NP_001273495. 0% 18 83.33% 401 NP_001273495. 0% 19 83.33% 108 KAI2579985.1 0% 23 83.33% 16 MEN4474536.1 1% 27 100.00% 12 MEN429365.1 1% 29 100.00% 13 MEN4432146.1 1% 30 100.00% 14 MEN4464420.1
Sequences p select all uncharacter vurcharac	Graphic Summary Alignments Taxonom producing significant alignments 100 sequences selected 100 sequences selected 100 sequences selected Description 100 sequences selected ized protein KIAA0513 isoform a [Homo sapiens] 100 sequences selected 100 sequences selected ized protein KIAA0513 isoform a [Homo sapiens] 100 sequences selected 100 sequences selected ized protein KIAA0513 isoform b [Homo sapiens] 100 sequences selected 100 sequences selected ized protein KIAA0513 isoform b [Homo sapiens] 100 sequences selected 100 sequences selected ized protein KI723_161508 [Homo sapiens] 100 sequences selected 100 sequences selected ized protein KI723_161508 [Homo sapiens] 100 sequences selected 100 sequences selected ized protein KI723_161508 [Homo sapiens] 100 sequences selected 100 sequences selected ized protein KI723_161508 [Homo sapiens] 100 sequences selected 100 sequences selected ized protein KI723_161508 [Homo sequences] 100 sequences selected 100 sequences selected ized protein KI723_161508 [Homo sequences] 100 sequences selected 100 sequences selected ized protein kin_reduction region [Homo sequences] 100 sequences selected 100 seque	Download Series GenPept Graphics Distance tree of a constraint of a constr	Persuits Multiple alignment MSA View ory E Per Acc. Accession 0% 18 83.33% 411 NP_001273494 0% 18 83.33% 401 NP_001273495 0% 18 83.33% 401 NP_001273495 0% 19 83.33% 198 KAI2570985.1 0% 23 83.33% 16 MBN4474536.1 1% 27 100.00% 12 MEN4429365.1 1% 29 100.00% 13 MEN4432146.1 1% 30 100.00% 14 MEN4424146.1 1% 30 100.00% 14 MEN4464120.1 1% 32 100.00% 15 MCA93912.1
Sequences p select all uncharacter vurcharac	Graphic Summary Alignments Taxonom producing significant alignments 100 sequences selected 100 sequences selected page 100 sequences selected Description 100 sequences page 100 sequences sequences 100 sequences 100 sequences page 100 sequences sequences 100 sequences 100 sequences page 100 sequenc	Scientific Name Max Total Or Scientific Name Max Total Or Homo sapiens 22.3 2.3 10 Homo sapiens 22.3 2.3 10 Homo sapiens 2.3 2.3 10 Homo sapiens 2.3 2.3 10 Homo sapiens 2.4 2.4 14 Homo sapiens 2.14 2.14 83	Persuits Multiple alignment MSA View ory E Per Ident Acc. Len Accession 0% 18 83.33% 411 NP_001273494 0% 18 83.33% 401 NP_001273494 0% 18 83.33% 401 NP_001273495. 0% 19 83.33% 198 KAI2579985.1 0% 23 83.33% 16 MBN4474536.1 1% 29 100.00% 12 MBN4299365.1 1% 29 100.00% 13 MEN4432146.1 1% 30 100.00% 14 MEN4424120.1 1% 30 100.00% 15 MCA93912.1 1% 35 100.00% 17 MEN4210426.1
Sequences p select all uncharacter uncharacter uncharacter uncharacter uncharacter uncharacter uncharacter unmunosib mmunosib mmunosib mmunosib mmunosib mmunosib mmunosib	Graphic Summary Alignments Taxonom producing significant alignments 100 sequences selected 100 sequences selected 100 sequences selected Description 100 sequences selected ized protein KIAA0513 isoform a [Homo sapiens] 100 sequences selected 100 sequences selected ized protein KIAA0513 isoform a [Homo sapiens] 100 sequences selected 100 sequences selected ized protein KIAA0513 isoform a [Homo sapiens] 100 sequences selected 100 sequences selected ized protein KIAA0513 isoform a [Homo sapiens] 100 sequences selected 100 sequences selected ized protein KIAA0513 isoform b [Homo sapiens] 100 sequences selected 100 sequences selected ized protein KI723_161508 [Homo sapiens] 100 sequences selected 100 sequences selected ized protein KI723_161508 [Homo sapiens] 100 hemo sapiens] 100 sequences selected ulin heavy chain junction region [Homo sapiens] 100 hemo sapiens] 100 sequences selected ulin heavy chain junction region [Homo sapiens] 100 hemo sapiens] 100 sequences selected	Download Series GenPept Graphics Distance tree of a constraint of a constr	Persuits Multiple alignment MSA View ory E Per Ident Acc. Len Accession 0% 18 83.33% 411 NP_001273494 0% 18 83.33% 401 NP_001273495 0% 18 83.33% 401 NP_001273495 0% 19 83.33% 198 KAI2579985.1 0% 23 83.33% 18 MEN4474536.1 1% 27 100.00% 12 MEN429365.1 1% 29 100.00% 13 MEN4432146.1 1% 30 100.00% 14 MEN442146.120.1 1% 30 100.00% 15 MCA93912.1 1% 35 100.00% 17 MEN4210426.1 1% 36 100.00% 18 MQR37821.1

Selection of the PoD and MoS calculation

References

CIR, 2012. Safety Assessment of α-Amino Acids as Used in Cosmetics, Final Report for Public Distribution. Cosmetic Ingredient Review, https://www.cir-safety.org/sites/default/files/amacid092012rep.pdf.

- ECHA, 2017. Read-across assessment framework (RAAF). https://echa.europa.eu/documents/10162/13628/raaf_en.pdf/614e5d61-891d-4154-8a47-87efebd1851a
- NCBI, 2024. BLAST [®] » blastp suite. <u>https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins.</u>
- EMEA. 1998. Committee for veterinary medical products: Bacitracin summary report. Report No. EMEA/MRL/451/98-FINAL, https://www.ema.europa.eu/en/documents/mrl-report/bacitracin-summary-report-committee-veterinary-medicinal-products_en.pdf.
- EU, 2009. Regulation (EC) No 1223/2009 of the European parliament and of the council of 30 November 2009 on cosmetic products. L 342/59. Official Journal of the European Union, <u>https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32009R1223&from=EN</u>.
- JECFA, 2006. Amino acids and related substances, safety evaluation of certain food additives and contaminants, sixty-third meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA). Report No. 54, http://whqlibdoc.who.int/publications/2006/9241660546 eng.pdf
- Judson PN et al., 2015. Assessing confidence in predictions using veracity and utility A case study on the prediction of mammalian metabolism by Meteor Nexus. Mol Inform 34 (5):284-291.
- Yuan K, et al. 2018. Antimicrobial peptide based magnetic recognition elements and Au@Ag-GO SERS tags with stable internal standards: a three in one biosensor for isolation, discrimination and killing of multiple bacteria in whole blood. Chem Sci 9 (47):8781-8795.

21.4 21.4 83% 36 100.00% 1380 XP 047290920

Figure 2: Blast analysis

Safety assessment	•	The skin and eye irritation, skin sensitisation, Ames test, and phototoxicity endpoints were addressed using <i>in vitro</i> data on peptide A.
based on a weight-of- evidence approach	•	The acute toxicity, repeated dose toxicity, clastogenicity, carcinogenicity, reproductive and developmental toxicity endpoints were addressed using the <i>in vivo</i> data available for the analogue bacitracin. BLAST analysis confirmed a similarity with a region of an endogenous human protein The systemic toxicity was further supported by the safety data on the individual amino acids, as an <i>in vitro</i> study using hepatocytes supported a high rate of metabolism and clearance of the peptide A.
Determination of the PoD and MoS calculations	•	Based on the available studies, a LOAEL of 11 mg/kg bw/day derived from a 13-week rat study available for bacitracin was established as the most relevant PoD for the safety assessment of the peptide A. A comparison of the systemic exposure dose of peptide A with the PoD resulted in an MoS of >1000, which is well above the threshold of 100 for concluding safe use.

intraflagellar transport protein 140 homolog isoform X2 [Homo sapiens]

Conclusion

Based on 1) in vitro experimental data, 2) in vivo data on the suitable analogue, 3) supporting data from the Blast analysis and individual amino acids, an appropriate PoD for systemic toxicity and a sufficiently high MoS can be established under the use condition of the cosmetic product.

www.toxminds.com